Oruka Therapeutics (NASDAQ:ORKA) Earns Buy Rating from Analysts at TD Cowen

TD Cowen began coverage on shares of Oruka Therapeutics (NASDAQ:ORKA) in a research note released on Monday morning, MarketBeat.com reports. The brokerage issued a buy rating on the stock.

Other equities analysts also recently issued research reports about the company. Jefferies Financial Group started coverage on Oruka Therapeutics in a research report on Friday, September 13th. They set a buy rating and a $40.00 price target for the company. Wedbush started coverage on Oruka Therapeutics in a research report on Wednesday, September 4th. They set an outperform rating and a $40.00 price target for the company. Four research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the stock. According to MarketBeat.com, Oruka Therapeutics currently has a consensus rating of Buy and a consensus price target of $41.25.

Oruka Therapeutics Price Performance

NASDAQ:ORKA opened at $25.38 on Monday. Oruka Therapeutics has a twelve month low of $18.72 and a twelve month high of $53.88.

About Oruka Therapeutics

ARCA biopharma, Inc, a biopharmaceutical company, develops genetically-targeted therapies for heart failure and cardiovascular diseases. It is positioned to bring personalized therapies for the treatment of cardiovascular disease, through the use of genetics. Complementing the Company’s cardiovascular science, ARCA’s management team has significant experience in developing and commercializing cardiovascular products.